Financial Performance - The company reported a significant increase in revenue, with a year-on-year growth of 25% in the first half of 2023, reaching a total revenue of 500 million RMB[1]. - The company has set a revenue guidance for the second half of 2023, projecting an additional 20% growth, aiming for a total revenue of 600 million RMB by year-end[1]. - The company's revenue for the first half of 2023 was approximately ¥178.71 million, representing a decrease of 14.16% compared to ¥208.18 million in the same period last year[30]. - The net profit attributable to shareholders was a loss of approximately ¥2.30 million, a decline of 111.95% from a profit of ¥19.25 million in the previous year[30]. - The basic and diluted earnings per share were both reported at -¥0.01, a decline of 114.29% from ¥0.07 in the same period last year[30]. - The total operating revenue for the first half of 2023 was CNY 178.71 million, a decrease of 14.2% compared to CNY 208.18 million in the same period of 2022[173]. - The total profit for the first half of 2023 was -1,520,428.81 yuan, a significant decline from 23,951,971.46 yuan in the same period of 2022[179]. - The company reported a net profit margin of 7.5%, showcasing improved operational efficiency compared to the previous period[191]. User Engagement and Market Presence - User data indicates that the number of active users of the digital hospital solutions has grown by 30%, now totaling 1.2 million users[1]. - The company is expanding its market presence, targeting an increase in market share by 10% in the next fiscal year through strategic partnerships with major healthcare institutions[1]. - The company is actively expanding its market presence with significant projects in Xi'an and Shaoxing, each valued over ¥10 million[45]. - The company has established long-term partnerships with major medical institutions across various provinces, enhancing its brand image and accumulating successful case studies in clinical information technology[67]. - The company plans to expand its market presence by launching new products in the second half of the year, targeting a 10% increase in market share[191]. Research and Development - The company has allocated 15% of its revenue towards R&D, focusing on innovative technologies in healthcare information systems[1]. - New product developments include an upgraded version of the clinical management information system, which is expected to enhance operational efficiency by 15% for clients[1]. - Research and development expenses increased by 2.63% to ¥33,198,624.21, compared to ¥32,349,035.12 in the same period last year[71]. - The company has initiated new product development strategies aimed at enhancing market competitiveness, although specific financial impacts were not disclosed[195]. - The company plans to enhance its product offerings and service capabilities in the medical information systems sector[200]. Financial Management and Investments - The company will not distribute cash dividends for the current fiscal year, opting to reinvest profits into growth initiatives[1]. - The company has not made any significant equity investments during the reporting period[85]. - The company has not undergone any changes in the use of raised funds for investment projects[93]. - The total amount of funds raised was RMB 49,631.96 million, with a cumulative investment of RMB 10,123.16 million as of the report date[88]. - The company has temporarily used 50 million yuan of idle raised funds to supplement working capital as of June 30, 2023[92]. Operational Challenges and Risks - The company is actively addressing risks related to client retention, implementing a new customer service strategy aimed at reducing churn by 5%[1]. - The company experienced a significant decline in operating income due to slower-than-expected recovery in customer demand, reflecting the cyclical nature of the industry[55]. - The company faces risks related to large system solution implementation, including project planning defects and key technology development failures[100]. - The company acknowledges potential uncertainties from changes in national policies and macroeconomic conditions affecting its operations[102]. Governance and Compliance - The company has a governance structure in place to protect shareholder rights and ensure compliance with relevant laws[115]. - The company has implemented measures to protect employee rights and promote their health and safety[115]. - The company reported no significant related party transactions during the reporting period[131]. - The company has maintained strong relationships with suppliers and customers, focusing on mutual growth and quality control[116]. Future Outlook - The company plans to focus on the development of "smart hospitals" and "digital health cities," launching new products and services based on digital platforms to create greater value for customers[60]. - The company is positioned to capitalize on the integration of digital technology in healthcare, enhancing service models and improving healthcare delivery efficiency[59]. - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[188].

单位：万元 浙江和仁科技股份有限公司 2023 年 1-6 月非经营性资金占用及其他关联资金往来情况汇总表 | 非经营性资金占用 | 资金占用方 | 占用方与上 市公司的关 | 上市公司核 算的会计科 | 2023 年 期初 | 2023 年 1-6 月占用累计发 | 2023 年 1-6 月占 用资金的 | 2023 年 1-6 月偿 还累计 | 2023 年 6 月 末 | 占用形成 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 名称 | 联关系 | 目 | 占用资金 余额 | 生金额 （不含利息） | 利息 | 发生金 | 占用资金余 额 | 原因 | | | | | | | | | （如有） | 额 | | | | | 控股股东、实际控制人及 | | | | | | | | | | 非经营性占用 | | 其附属企业 | | | | | | | | | | | | 小计 | - | | | | | | | | | - | | 前控股股东、实际控制人 及其附属企业 | | | | | | | ...

（二）、变更日期 公司根据上述会计准则解释规定，对会计政策进行相应变更，并按规定自 2023 年 1 月 1 日起执行。 浙江和仁科技股份有限公司 关于会计政策变更的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 浙江和仁科技股份有限公司（以下简称"公司"）根据中华人民共和国财政 部（以下简称"财政部"）颁布的企业会计准则变更相应的会计政策，本次会计 政策变更无需董事会和股东大会审议。相关会计政策变更的具体情况如下： 一、本次会计政策变更的概述 （一）、会计政策变更原因说明 2022 年 11 月 30 日，财政部颁布了《企业会计准则解释第 16 号》——关于 单项交易产生的资产和负债相关的递延所得税不适用初始确认豁免的会计处理， 自 2023 年 1 月 1 日起执行。 证券代码：300550 证券简称：和仁科技 公告编号：2023-048 本次会计政策变更是公司根据财政部相关规定和要求进行的变更，符合相关 法律法规的规定，执行变更后的会计政策能够客观、公允地反映公司的财务状况 和经营成果。本次会计政策变更不会对公司财务状况、经营成果和现金流量产生 重 ...

浙江和仁科技股份有限公司 独立董事关于第四届董事会第二次会议 （本页为《浙江和仁科技股份有限公司独立董事关于第四届董事会第二次会议 相关事项的独立意见》的签署页，无正文） 独立董事签名： 黄 海： 相关事项的独立意见 根据《上市公司独立董事规则》、《上市公司自律监管指引第2号——创 业板上市公司规范运作》和《公司章程》的有关规定，我们作为公司独立董 事，对公司第四届董事会第二次会议相关事项进行了审议，并仔细阅读了公司 提供的相关资料。现基于独立判断立场，发表独立意见如下： 一、关于对关联方占用资金情况和对外担保的独立意见 1、截止2023年6月30日，公司控股股东不存在占用公司资金的情况，也不 存在以前年度发生并累计至2023年6月30日的违规关联方占用资金情况。 2、截止 2023 年 6 月 30 日，公司未发生对外担保的情况，也不存在以前年 度发生并累计至 2023 年 6 月 30 日的其他任何形式的对外担保情况。 二、关于公司2023年半年度募集资金存放与实际使用情况的独立意见 经核查，公司编制的《2023 年半年度募集资金存放与使用情况的专项报告》 内容真实、准确、完整、不存在虚假记录、误导性陈述 ...

根据中国证券监督管理委员会《上市公司监管指引第 2 号——上市公司募集资金管理和 使用的监管要求（2022 年修订）》（证监会公告〔2022〕15 号）和深圳证券交易所印发的 《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》（深证上 〔2022〕14 号）的规定，将本公司募集资金 2023 年 1-6 月存放与使用情况专项说明如下。 一、募集资金基本情况 (一) 实际募集资金金额和资金到账时间 经中国证券监督管理委员会证监许可（2020）1243 号文核准，并经深圳证券交易所同 意，本公司由主承销商海通证券股份有限公司采用非公开发行的方式，向特定对象发行人民 币普通股（A 股）股票 25,862,558 股，发行价为每股人民币 19.61 元，共计募集资金 507,164,762.38 元，坐扣承销和保荐费用 7,547,169.81 元后的募集资金为 499,617,592.57 元，已由主承销商海通证券股份有限公司于 2020 年 9月 30日汇入本公司募集资金监管账户。 另减除申报会计师费、律师费、证券登记费等与发行权益性证券直接相关的新增外部费用 3,297,983.47 元 ...

一、董事会会议召开情况 证券代码：300550 证券简称：和仁科技 公告编号：2023-046 浙江和仁科技股份有限公司 第四届董事会第二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 2、审议通过《关于公司 2023 年半年度报告全文及摘要的议案》 表决结果：7 票同意，0 票反对，0 票弃权 《2023 年半年度报告全文及摘要》详见信息披露网站巨潮资讯网 （http://www.cninfo.com.cn）。 三、备查文件 浙江和仁科技股份有限公司（以下简称"公司"）第四届董事会第二次会议 于 2023 年 8 月 17 日以通讯表决方式召开。 召开本次会议的通知已于 2023 年 8 月 11 日以电子邮件形式送达各位董事。 本次董事会会议应参与表决董事 7 名，实际参与表决董事 7 名，符合《公司法》 及《公司章程》的规定。本次会议的召集、召开及表决程序符合《公司法》等法 律、法规、规范性文件以及《公司章程》的有关规定。 二、董事会会议审议情况 经与会董事审议并在议案表决票上签字表决，审议通过如下议案： 1、审议通过《关于公司 2023 ...

证券代码：300550 证券简称：和仁科技 公告编号：2023-047 浙江和仁科技股份有限公司 第四届监事会第二次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 浙江和仁科技股份有限公司（以下简称"公司"）第四届监事会第二次会议 于 2023 年 8 月 17 日在公司会议室以现场结合通讯表决的方式召开。 召开本次会议的通知已于 2023 年 8 月 11 日以电子邮件方式通知各位监事。 会议应参与表决监事3名，实际参与会议表决监事3名，此次会议达到法定人数， 符合《公司法》和《公司章程》的规定。 二、监事会会议审议情况 经与会监事审议并在议案表决票上签字表决，审议通过如下议案： 1、审议通过《关于公司 2023 年半年度募集资金存放与实际使用情况的专 项报告的议案》 表决结果： 3 票同意，0 票反对，0 票弃权 经审核，监事会认为： 公司募集资金的管理、使用及运作程序符合《深圳证券交易所创业板股票 上市规则》、《上市公司自律监管指引第 2 号——创业板上市公司规范运作》等 有关法律法规及《公司章程》等公司制度的规定， ...

股票代码：300550 股票简称：和仁科技 编号：2023-001 投资者关系活动类 □特定对象调研 □分析师会议 别 □媒体采访 √业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他 （请文字说明其他活动内容） 参与单位名称及人 线上参与公司和仁科技 2022 年度网上业绩说明会的投 员姓名 资者 时间 2023 年 05 月 12 日（星期五）下午 15:00-17:00 地点 "和仁科技投资者关系"微信小程序 总经理：赵晨晖 上市公司接待人员 副总经理兼董事会秘书：章逸 姓名 财务负责人：张雪峰 独立董事：蔡钰如 一、问：总经理您好！对于 2023 年企业有什么规划？如 何增强投资者信心？ 答：尊敬的投资者，您好，公司 2023 主要规划如下： 1、在业务发展方面，公司将加强营销网络建设和营销投 入，在各地大型医院及空白县域医院目标市场中，为大 型医院提供提供总包式系统性建设，提供软硬件一体化 投资者关系活动主 配置、整体系统集成调试、系统维保在内的医疗信息系 要内容介绍 统整体交付服务及系统性解决方案。为县域医院提供标 准化程度更高，交付边界更清晰的信息化产品，不断拓 展二级医院为主的县域公立医 ...

证券代码：300550 证券简称：和仁科技 公告编号：2023-035 浙江和仁科技股份有限公司 关于召开2022年度网上业绩说明会的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，不存在虚假记 载、误导性陈述或者重大遗漏。 浙江和仁科技股份有限公司（以下简称"公司"）已于2023年04月27日在巨潮资讯网 （http://www.cninfo.com.cn/）上披露了《和仁科技2022年年度报告》。 为便于广大投资者进一步了解公司2022年年度经营情况，公司定于2023年05月12日（星期 五）下午15:00至17:00时在"和仁科技投资者关系"小程序举行2022年度网上业绩说明会。本 次网上业绩说明会将采用网络远程的方式举行，投资者可登陆"和仁科技投资者关系"小程序 参与互动交流。为广泛听取投资者的意见和建议，提前向投资者征集问题，提问通道自发出公 告之日起开放。 参与方式一：在微信小程序中搜索"和仁科技投资者关系"； 投资者依据提示，授权登入"和仁科技投资者关系"小程序，即可参与交流。 出席本次网上说明会的人员有：总经理赵晨晖，副总经理兼董事会秘书章逸，财务负责人 张雪峰，独立董事蔡钰如。 敬 ...

Financial Performance - The company reported a net profit attributable to shareholders of -83.31 million yuan in 2022, a decrease of 341.60% year-on-year, primarily due to delays in clients' planned IT investments and reduced sales collection[3]. - The company's operating revenue for 2022 was ¥360,330,264.95, a decrease of 22.38% compared to ¥464,199,738.03 in 2021[30]. - The net profit attributable to shareholders of the listed company was -¥34,807,299.12 in 2022, a decline of 341.60% from ¥43,142,792.70 in 2021[30]. - The net cash flow from operating activities was -¥89,170,980.5 in 2022, a significant decrease of 396.02% compared to ¥67,562,479.6 in 2021[30]. - The basic earnings per share for 2022 was -¥0.32, down 346.15% from ¥0.18 in 2021[30]. - The company reported a quarterly operating revenue of ¥57,408,318.84 in Q4 2022, a decline compared to previous quarters[32]. - The net profit attributable to shareholders in Q4 2022 was -¥108,096,810.90, indicating significant losses in that quarter[32]. - The company recognized non-operating income of ¥3,497,364.09 in 2022, down from ¥7,708,448.40 in 2021[36]. - The company has indicated that its net profit before deducting non-recurring gains and losses has been negative for the last three accounting years[30]. - The company reported a net profit margin of 10.9% for the year 2022, indicating strong profitability amidst market challenges[172]. Revenue and Growth - Zhejiang Heren Technology Co., Ltd. reported a revenue of RMB 500 million for the fiscal year 2022, representing a year-on-year growth of 15%[22]. - The company achieved a net profit of RMB 80 million in 2022, which is an increase of 20% compared to the previous year[22]. - Heren Technology plans to expand its market presence by entering three new provinces in 2023, aiming for a 25% increase in market share[22]. - Heren Technology has set a revenue guidance of RMB 600 million for 2023, reflecting a growth target of 20%[22]. - The company reported a significant increase in revenue, achieving a total of 1.5 billion RMB for the year, representing a growth of 20% compared to the previous year[180]. - User data showed an increase in active users, reaching 2 million, which is a 15% increase year-over-year[180]. - The company provided guidance for the next fiscal year, projecting a revenue growth of 25% to 1.875 billion RMB[180]. Market Position and Strategy - The company is positioned as a provider of digital hospital solutions based on core software systems, facing implementation risks due to complex project requirements and longer implementation cycles[6]. - The company aims to enhance service quality and maintain customer stability by focusing on both existing and new client resources[8]. - The company is expanding its business structure from electronic medical records to comprehensive solutions, which increases management control challenges and may impact gross profit margins[9]. - The company is exploring potential acquisitions of smaller tech firms to enhance its product offerings and market reach[22]. - The company is positioned to benefit from the government's emphasis on digital health and the integration of new technologies like big data and AI in healthcare services[42]. - The company is focusing on the development of smart hospital solutions, integrating clinical medical information systems, operational management systems, IoT solutions, and new service systems, aiming for comprehensive market expansion[140]. Research and Development - The company is investing RMB 50 million in R&D for new digital hospital solutions, expected to launch in Q3 2023[22]. - The company’s R&D investment amounted to ¥67,484,894.64 in 2022, representing 18.73% of its operating revenue, an increase from 16.89% in 2021[104]. - The company has developed a new generation of hospital information systems based on HTML5 and cloud computing, which is currently the largest in the country[78]. - The company is currently testing a clinical research integration platform that combines clinical data with research needs, aimed at improving product competitiveness[101]. - The company aims to enhance its product competitiveness through various ongoing research and development projects focused on digital health solutions[100]. Customer Engagement and Satisfaction - The company reported a customer satisfaction rate of 90%, indicating strong user engagement and service quality[22]. - The company has established long-term partnerships with top-tier medical institutions across several provinces, enhancing its brand image and service quality[81]. - The company aims to enhance clinical information application levels in hospitals through standardized assessments and operational services, leading to increased value-added service revenue as project bases grow[152]. Challenges and Risks - The company faces risks from macroeconomic fluctuations, regulatory changes in the healthcare information industry, and accounts receivable recovery issues, which investors should be aware of[5]. - The company has faced challenges due to client budget adjustments and increased internal requirements, impacting new contract signing progress[52]. - The company has faced challenges due to weakened customer payment capabilities and industry fluctuations but remains committed to enhancing product competitiveness through sustained investment[73]. Governance and Compliance - The company maintains a strong governance structure, with independent directors constituting over one-third of the board, ensuring effective oversight and risk management[162]. - The company adheres to strict information disclosure regulations, ensuring transparency and effective communication with investors[163]. - The company has established an independent internal audit department to enhance the supervision and evaluation of internal control activities, ensuring the safety and integrity of company assets[164]. - The company has complied with all relevant laws and regulations, ensuring honest and compliant operations[164]. Human Resources and Management - The total number of employees at the end of the reporting period was 806, with 763 from the parent company and 43 from major subsidiaries[194]. - The company has implemented a comprehensive training plan to enhance employee professional skills and overall capabilities[196]. - The company aims to maintain competitive salary levels while ensuring fairness internally and externally[195]. - The company has established a performance evaluation and incentive mechanism for senior management to ensure transparency and compliance in hiring and compensation practices[162].